Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Effect of local anesthesia with lidocaine on perioperative proinflammatory cytokine levels in plasma and cerebrospinal fluid in cerebral aneurysm patients: Study protocol for a randomized clinical trial.

Matas M, Sotošek V, Kozmar A, Likić R, Sekulić A.

Medicine (Baltimore). 2019 Oct;98(42):e17450. doi: 10.1097/MD.0000000000017450.

PMID:
31626100
2.

Prognostic value of inositol polyphosphate-5-phosphatase expression in recurrent and metastatic cutaneous squamous cell carcinoma.

Maly CJ, Cumsky HJL, Costello CM, Schmidt JE, Butterfield RJ, Zhang N, DiCaudo DJ, Nelson SA, Smith ML, Ochoa SA, Baum CL, Nagel TH, Pittelkow MR, Sekulic A, Mangold AR.

J Am Acad Dermatol. 2019 Aug 19. pii: S0190-9622(19)32574-5. doi: 10.1016/j.jaad.2019.08.027. [Epub ahead of print]

PMID:
31437542
3.

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A; ERIVANCE BCC Investigators.

BMC Cancer. 2019 Apr 18;19(1):366. doi: 10.1186/s12885-019-5568-6.

4.

The prognostic value of inositol polyphosphate 5-phosphatase in cutaneous squamous cell carcinoma.

Cumsky HJL, Costello CM, Zhang N, Butterfield R, Buras MR, Schmidt JE, Drenner K, Nelson SA, Ochoa SA, Baum CL, Pittelkow MR, DiCaudo DJ, Sekulic A, Mangold AR.

J Am Acad Dermatol. 2019 Mar;80(3):626-632.e1. doi: 10.1016/j.jaad.2018.10.018. Epub 2018 Oct 22.

PMID:
30359624
5.

Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB.

Cancer. 2019 Jan 1;125(1):18-44. doi: 10.1002/cncr.31719. Epub 2018 Oct 3. Review. Erratum in: Cancer. 2019 Aug 1;125(15):2706.

PMID:
30281145
6.

Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.

Hendricks WPD, Zismann V, Sivaprakasam K, Legendre C, Poorman K, Tembe W, Perdigones N, Kiefer J, Liang W, DeLuca V, Stark M, Ruhe A, Froman R, Duesbery NS, Washington M, Aldrich J, Neff MW, Huentelman MJ, Hayward N, Brown K, Thamm D, Post G, Khanna C, Davis B, Breen M, Sekulic A, Trent JM.

PLoS Genet. 2018 Sep 6;14(9):e1007589. doi: 10.1371/journal.pgen.1007589. eCollection 2018 Sep.

7.

Network Rewiring in Cancer: Applications to Melanoma Cell Lines and the Cancer Genome Atlas Patients.

Ding KF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ.

Front Genet. 2018 Jul 10;9:228. doi: 10.3389/fgene.2018.00228. eCollection 2018.

8.

Clinical and histopathologic features of paraneoplastic granuloma annulare in association with solid organ malignancies: A case-control study.

Mangold AR, Cumsky HJL, Costello CM, Xie DY, Buras MR, Nelson SA, DiCaudo DJ, Sekulic A, Pittelkow MR.

J Am Acad Dermatol. 2018 Nov;79(5):913-920.e1. doi: 10.1016/j.jaad.2018.06.022. Epub 2018 Jun 18.

PMID:
29920319
9.

Evaluation of pre-analytical factors affecting plasma DNA analysis.

Markus H, Contente-Cuomo T, Farooq M, Liang WS, Borad MJ, Sivakumar S, Gollins S, Tran NL, Dhruv HD, Berens ME, Bryce A, Sekulic A, Ribas A, Trent JM, LoRusso PM, Murtaza M.

Sci Rep. 2018 May 9;8(1):7375. doi: 10.1038/s41598-018-25810-0.

10.

Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.

Lang JD, Hendricks WPD, Orlando KA, Yin H, Kiefer J, Ramos P, Sharma R, Pirrotte P, Raupach EA, Sereduk C, Tang N, Liang WS, Washington M, Facista SJ, Zismann VL, Cousins EM, Major MB, Wang Y, Karnezis AN, Sekulic A, Hass R, Vanderhyden BC, Nair P, Weissman BE, Huntsman DG, Trent JM.

Clin Cancer Res. 2018 Apr 15;24(8):1932-1943. doi: 10.1158/1078-0432.CCR-17-1928. Epub 2018 Feb 9.

11.

Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis.

Ding KF, Petricoin EF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ.

Oncotarget. 2017 Dec 15;9(4):5044-5057. doi: 10.18632/oncotarget.23495. eCollection 2018 Jan 12.

12.

Treatment of vismodegib-associated muscle cramps with cyclobenzaprine: A retrospective review.

Yang YW, Macdonald JB, Nelson SA, Sekulic A.

J Am Acad Dermatol. 2017 Dec;77(6):1170-1172. doi: 10.1016/j.jaad.2016.12.017. No abstract available.

PMID:
29132849
13.

Frequent loss of inositol polyphosphate-5-phosphatase in oropharyngeal squamous cell carcinoma.

Patel AB, Mangold AR, Costello CM, Nagel TH, Smith ML, Hayden RE, Sekulic A.

J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e36-e37. doi: 10.1111/jdv.14462. Epub 2017 Aug 2. No abstract available.

14.

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A; ERIVANCE BCC Investigators.

BMC Cancer. 2017 May 16;17(1):332. doi: 10.1186/s12885-017-3286-5. Erratum in: BMC Cancer. 2019 Apr 18;19(1):366.

15.

Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma.

Liang WS, Hendricks W, Kiefer J, Schmidt J, Sekar S, Carpten J, Craig DW, Adkins J, Cuyugan L, Manojlovic Z, Halperin RF, Helland A, Nasser S, Legendre C, Hurley LH, Sivaprakasam K, Johnson DB, Crandall H, Busam KJ, Zismann V, Deluca V, Lee J, Sekulic A, Ariyan CE, Sosman J, Trent J.

Genome Res. 2017 Apr;27(4):524-532. doi: 10.1101/gr.213348.116.

16.

Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses.

Ding KF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ.

Oncotarget. 2017 Apr 25;8(17):27786-27799. doi: 10.18632/oncotarget.15347.

17.

Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.

Chang AL, Lewis KD, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A.

Oncotarget. 2016 Nov 15;7(46):76118-76124. doi: 10.18632/oncotarget.12660.

18.

A Pharmacological Chaperone Molecule Induces Cancer Cell Death by Restoring Tertiary DNA Structures in Mutant hTERT Promoters.

Kang HJ, Cui Y, Yin H, Scheid A, Hendricks WPD, Schmidt J, Sekulic A, Kong D, Trent JM, Gokhale V, Mao H, Hurley LH.

J Am Chem Soc. 2016 Oct 19;138(41):13673-13692. doi: 10.1021/jacs.6b07598. Epub 2016 Oct 5.

PMID:
27643954
19.

Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.

Chang AL, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A.

Orphanet J Rare Dis. 2016 Sep 1;11(1):120. doi: 10.1186/s13023-016-0506-z.

20.

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.

Lacouture ME, Dréno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R.

Oncologist. 2016 Oct;21(10):1218-1229. Epub 2016 Aug 10. Review.

21.

Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Higgins SA, Ho AL, Lewis KD, Lydiatt DD, Nehal KS, Nghiem P, Olsen EA, Schmults CD, Sekulic A, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Wong SL, Zic JA, Hoffmann KG, Engh A.

J Natl Compr Canc Netw. 2016 May;14(5):574-97.

PMID:
27160235
22.

Risk Factors Predicting Positive Margins at Primary Wide Local Excision of Cutaneous Melanoma.

Mangold AR, Skinner R, Dueck AC, Sekulic A, Pockaj BA.

Dermatol Surg. 2016 May;42(5):646-52. doi: 10.1097/DSS.0000000000000702.

PMID:
27082057
23.

Hedgehog Pathway Inhibition.

Sekulic A, Von Hoff D.

Cell. 2016 Feb 25;164(5):831. doi: 10.1016/j.cell.2016.02.021.

24.

Analysis of the factors influencing development of urinary tract infections in patients with spinal cord injuries.

Sekulić A, Nikolić AK, Bukumirić Z, Trajković G, Corac A, Janković S, Milićević S.

Vojnosanit Pregl. 2015 Dec;72(12):1074-9.

PMID:
26898030
25.

Association of liprin β-1 with kank proteins in melanoma.

Luo M, Mengos AE, Mandarino LJ, Sekulic A.

Exp Dermatol. 2016 Apr;25(4):321-3. doi: 10.1111/exd.12933. Epub 2016 Feb 26. No abstract available.

26.

Chronic interstitial granulomatous dermatitis in coccidioidomycosis.

Mangold AR, DiCaudo DJ, Blair JE, Sekulic A.

Br J Dermatol. 2016 Apr;174(4):881-884. doi: 10.1111/bjd.14295. Epub 2016 Feb 3.

PMID:
26574343
27.

Scoring Systems in Assessing Survival of Critically Ill ICU Patients.

Sekulic AD, Trpkovic SV, Pavlovic AP, Marinkovic OM, Ilic AN.

Med Sci Monit. 2015 Sep 4;21:2621-9. doi: 10.12659/MSM.894153.

28.

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.

LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM.

Mol Cancer Ther. 2015 Aug;14(8):1962-71. doi: 10.1158/1535-7163.MCT-15-0153. Epub 2015 Jun 10.

29.

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.

Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, Hauschild A; ERIVANCE BCC investigators.

J Am Acad Dermatol. 2015 Jun;72(6):1021-6.e8. doi: 10.1016/j.jaad.2015.03.021.

PMID:
25981002
30.

Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion.

Sekulic A, Liang WS, Tembe W, Izatt T, Kruglyak S, Kiefer JA, Cuyugan L, Zismann V, Legendre C, Pittelkow MR, Gohmann JJ, De Castro FR, Trent J, Carpten J, Craig DW, McDaniel TK.

Mol Genet Genomic Med. 2015 Mar;3(2):130-6. doi: 10.1002/mgg3.121. Epub 2014 Nov 27.

31.

Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.

Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A.

J Am Acad Dermatol. 2015 Feb;72(2):221-36; quiz 237-8. doi: 10.1016/j.jaad.2014.07.033. Review.

PMID:
25592339
32.

Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.

Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A.

J Am Acad Dermatol. 2015 Feb;72(2):203-18; quiz 219-20. doi: 10.1016/j.jaad.2014.07.032. Review.

PMID:
25592338
33.

Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma.

Mangold AR, Bryce A, Sekulic A.

J Am Acad Dermatol. 2014 Nov;71(5):e205-6. doi: 10.1016/j.jaad.2014.03.043. Epub 2014 Oct 15. No abstract available.

34.

Influence of spinal and general anesthesia on the metabolic, hormonal, and hemodynamic response in elective surgical patients.

Milosavljevic SB, Pavlovic AP, Trpkovic SV, Ilić AN, Sekulic AD.

Med Sci Monit. 2014 Oct 6;20:1833-40. doi: 10.12659/MSM.890981.

35.

Peripheral arterial catheter related infections in the neurosurgical intensive care unit.

Radonić J, Mihaljević L, Radonić R, Rogić D, Sekulić A, Katancić-Holjevac J, Murselović T, Stambolija V.

Coll Antropol. 2014 Jun;38(2):665-9.

PMID:
25145004
36.

Age and individual sleep characteristics affect cognitive performance in anesthesiology residents after a 24-hour shift.

Tadinac M, Sekulić A, Hromatko I, Mazul-Sunko B, Ivancić R.

Acta Clin Croat. 2014 Mar;53(1):22-30.

PMID:
24974663
37.

[Outcome among patients suffering from in-hospital cardiac arrest].

Trpković S, Pavlović A, Bumbasirević V, Sekulić A, Milicić B.

Srp Arh Celok Lek. 2014 Mar-Apr;142(3-4):170-7. Serbian.

38.

Treatment of epidermolysis bullosa pruriginosa using systemic and topical agents.

Mangold AR, Cole CM, DiCaudo DJ, Pittelkow MR, Sekulic A.

J Am Acad Dermatol. 2014 Jun;70(6):e136-7. doi: 10.1016/j.jaad.2013.12.011. No abstract available.

39.

Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.

Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, Corneveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kiefer J, Zismann VL, McEachron TA, Salhia B, Prat J, D'Angelo E, Clarke BA, Pressey JG, Farley JH, Anthony SP, Roden RB, Cunliffe HE, Huntsman DG, Trent JM.

Nat Genet. 2014 May;46(5):427-9. doi: 10.1038/ng.2928. Epub 2014 Mar 23.

40.

Meeting report from the 10th International Congress of the Society for Melanoma Research, Philadelphia, PA, November 2013.

Vultur A, O'Connell M, Webster M, Villanueva J, Herlyn D, Somasundaram R, Krepler C, Zaidi R, Patton E, Sekulic A, Jonsson G, Weeraratna AT.

Pigment Cell Melanoma Res. 2014 Jul;27(4):E1-E12. doi: 10.1111/pcmr.12240. Epub 2014 May 6. No abstract available.

41.

Analysis of the factors influencing functional outcomes in patients with spinal cord injury.

Milicevic S, Piscevic V, Bukumiric Z, Nikolic AK, Sekulic A, Corac A, Babovic R, Jankovic S.

J Phys Ther Sci. 2014 Jan;26(1):67-71. doi: 10.1589/jpts.26.67. Epub 2014 Feb 6.

42.

Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease.

McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, Hou J, Wang L, Yue H, Hauschild A.

Eur J Cancer. 2014 Mar;50(4):774-83. doi: 10.1016/j.ejca.2013.12.013. Epub 2014 Jan 9. Review.

43.

Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).

Ramos P, Karnezis AN, Hendricks WP, Wang Y, Tembe W, Zismann VL, Legendre C, Liang WS, Russell ML, Craig DW, Farley JH, Monk BJ, Anthony SP, Sekulic A, Cunliffe HE, Huntsman DG, Trent JM.

Rare Dis. 2014 Nov 3;2(1):e967148. doi: 10.4161/2167549X.2014.967148. eCollection 2014.

44.

Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway.

Sekulic A, Mangold AR, Northfelt DW, LoRusso PM.

Curr Opin Oncol. 2013 May;25(3):218-23. doi: 10.1097/CCO.0b013e32835ff438. Review.

PMID:
23493193
45.

Clonal evolution and therapeutic resistance in solid tumors.

Barrett MT, Lenkiewicz E, Evers L, Holley T, Ruiz C, Bubendorf L, Sekulic A, Ramanathan RK, Von Hoff DD.

Front Pharmacol. 2013 Jan 28;4:2. doi: 10.3389/fphar.2013.00002. eCollection 2013.

46.

[Pathophysiology of delirium].

Bogović TZ, Tonković D, Sekulić A, Bandić-Pavlović D, Baronica R, Bogović M, Sakan S, Grcić IF, Tomasević B.

Acta Med Croatica. 2012 Mar;66(1):61-6. Review. Croatian.

PMID:
23088089
47.

[Does the anesthesiologist sleep soundly?].

Sekulić A, Sunko BM, Tadinac M.

Acta Med Croatica. 2012 Mar;66(1):55-60. Review. Croatian.

PMID:
23088088
48.

[Word recognition test after general anesthesia: the influence of previous anesthesia].

Skok I, Sekulić A, Mikulandra S.

Acta Med Croatica. 2012 Mar;66(1):7-10. Croatian.

PMID:
23088079
49.

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A.

N Engl J Med. 2012 Jun 7;366(23):2171-9. doi: 10.1056/NEJMoa1113713.

50.

Malignant melanoma in the elderly: different regional disease and poorer prognosis.

Macdonald JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, Sekulic A, Pockaj BA.

J Cancer. 2011;2:538-43. Epub 2011 Nov 1.

Supplemental Content

Loading ...
Support Center